substance-solution: packs Reg. No.: LSR-007009/08

Clinical and pharmacological group:

Release form, composition and packaging

substance -solution.

bottles (1) - cardboard packs.

Description of the active components of the drug " Interferon alpha-2b»

pharmachologic effect

Interferon. It is a highly purified recombinant protein with a molecular weight of 19,300 daltons. Obtained from an Escherichia coli clone by hybridizing bacterial plasmids with the human leukocyte gene encoding the synthesis of interferon. Unlike interferon, alpha-2a has arginine at position 23.

It has an antiviral effect, which is due to interaction with specific membrane receptors and induction of RNA synthesis and, ultimately, proteins. The latter, in turn, prevent the normal reproduction of the virus or its release.

It has immunomodulatory activity, which is associated with the activation of phagocytosis, stimulation of the formation of antibodies and lymphokines.

Has an antiproliferative effect on tumor cells.

Indications

Acute hepatitis B, chronic hepatitis B, chronic hepatitis C.

Hairy cell leukemia, chronic myeloid leukemia, renal cell carcinoma, Kaposi's sarcoma due to AIDS, cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome), malignant melanoma.

Dosage regimen

Administered intravenously or subcutaneously. The dose and treatment regimen are set individually, depending on the indications.

Side effect

Flu-like symptoms: often - fever, chills, pain in bones, joints, eyes, myalgia, headache, increased sweating, dizziness.

From the digestive system: possible decreased appetite, nausea, vomiting, diarrhea, constipation, impaired taste, dry mouth, weight loss, mild abdominal pain, slight changes in liver function tests (usually normalized after treatment).

From the central nervous system and peripheral nervous system: rarely - dizziness, deterioration of mental activity, sleep disturbance, memory impairment, anxiety, nervousness, aggressiveness, euphoria, depression (after long-term treatment), paresthesia, neuropathy, tremor; in some cases - suicidal tendencies, drowsiness.

From the cardiovascular system: possible - tachycardia (with fever), arterial hypotension or hypertension, arrhythmia; in some cases - disorders of the cardiovascular system, coronary artery disease, myocardial infarction.

From the respiratory system: rarely - chest pain, cough, slight shortness of breath; in some cases - pneumonia, pulmonary edema.

From the hematopoietic system: possible slight leukopenia, thrombocytopenia, granulocytopenia.

Dermatological reactions: possible itching, reversible alopecia.

Others: rarely - muscle stiffness; in isolated cases - antibodies to natural or recombinant interferons.

Contraindications

Severe cardiovascular diseases, decompensated liver cirrhosis, severe depression, psychosis, alcohol or drug addiction, increased sensitivity to interferon alpha-2b.

Pregnancy and lactation

Use during pregnancy is possible only if the expected benefit of therapy for the mother outweighs the potential risk to the fetus.

It is not known whether interferon alfa-2b is excreted in breast milk. If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.

Women of childbearing age should use reliable contraception during treatment.

Use for liver dysfunction

Contraindicated in decompensated liver cirrhosis. Use with caution in patients with impaired liver function.

Use for renal impairment

Use with caution in patients with impaired renal function.

special instructions

Use with caution in patients with impaired renal, liver, bone marrow hematopoiesis, or with a tendency to suicide attempts.

In patients with diseases of the cardiovascular system, arrhythmia is possible. If the arrhythmia does not decrease or increases, the dose should be reduced by 2 times or treatment should be stopped.

During the treatment period, monitoring of neurological and mental status is necessary.

In cases of severe suppression of bone marrow hematopoiesis, regular examination of the composition of peripheral blood is necessary.

Interferon alfa-2b has a stimulating effect on the immune system and should be used with caution in patients prone to autoimmune diseases due to an increased risk of autoimmune reactions.

Drug interactions

Drug interactions

Interferon alfa-2b inhibits the metabolism of theophylline and reduces its clearance.

Release form, composition and packaging

Injection transparent, colorless.

Excipients:

0.5 ml - ampoules (5) - contour cell packaging (1) - cardboard packs.
0.5 ml - ampoules (5) - contour cell packaging (2) - cardboard packs.
0.5 ml - bottles (1) - cardboard packs.
0.5 ml - bottles (5) - contour cell packaging (1) - cardboard packs.
0.5 ml - glass syringes (1) - contour cell packaging (1) - cardboard packs.
0.5 ml - glass syringes (1) - contour cell packaging (3) - cardboard packs.
0.5 ml - glass syringes (3) - contour cell packaging (1) - cardboard packs.
0.5 ml - glass syringes (3) - contour cell packaging (3) - cardboard packs.

Injection transparent, colorless.

Excipients: sodium acetate, sodium chloride, ethylenediamine tetraacetic acid disodium salt, Tween-80, dextran 40, water for injection.

1 ml - ampoules (5) - contour cell packaging (1) - cardboard packs.
1 ml - ampoules (5) - contour cell packaging (2) - cardboard packs.
1 ml - bottles (1) - cardboard packs.
1 ml - bottles (5) - contour cell packaging (1) - cardboard packs.
1 ml - glass syringes (1) - contour cell packaging (1) - cardboard packs.
1 ml - glass syringes (1) - contour cell packaging (3) - cardboard packs.
1 ml - glass syringes (3) - contour cell packaging (1) - cardboard packs.
1 ml - glass syringes (3) - contour cell packaging (3) - cardboard packs.

Clinical and pharmacological group

pharmachologic effect

Interferon. Altevir ® has antiviral, immunomodulatory, antiproliferative and antitumor effects.

Interferon alpha-2b, interacting with specific receptors on the cell surface, initiates a complex chain of changes inside the cell, including the induction of the synthesis of a number of specific cytokines and enzymes, and disrupts the synthesis of viral RNA and viral proteins in the cell. The result of these changes is nonspecific antiviral and antiproliferative activity associated with the prevention of viral replication in the cell, inhibition of cell proliferation and the immunomodulatory effect of interferon. Interferon alpha-2b stimulates the process of antigen presentation to immunocompetent cells, has the ability to stimulate the phagocytic activity of macrophages, as well as the cytotoxic activity of T cells and “natural killer” cells involved in antiviral immunity.

Prevents cell proliferation, especially tumor cells. It has an inhibitory effect on the synthesis of some oncogenes, leading to inhibition of tumor growth.

Pharmacokinetics

Suction

With subcutaneous or intramuscular administration of interferon alfa-2b, its bioavailability ranges from 80% to 100%. After the administration of interferon alpha-2b, T max in the blood plasma is 4-12 hours, T 1/2 - 2-6 hours. 16-24 hours after administration, recombinant interferon is not detected in the blood serum.

Metabolism

Metabolism occurs in the liver.

Alpha interferons can disrupt oxidative metabolic processes, reducing the activity of microsomal liver enzymes of the cytochrome P450 system.

Removal

It is excreted mainly by the kidneys by glomerular filtration.

Indications for use of the drug

As part of complex therapy in adults:

- with chronic viral hepatitis B without signs of liver cirrhosis;

- for chronic viral hepatitis C in the absence of symptoms of liver failure (monotherapy or combination therapy with ribavirin);

- with papillomatosis of the larynx;

- for genital warts;

- for hairy cell leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, melanoma, multiple myeloma, Kaposi's sarcoma against the background of AIDS, progressive kidney cancer.

Dosage regimen

Apply subcutaneously, intramuscularly and intravenously. Treatment must be started by a doctor. Then, with the doctor’s permission, the patient can administer a maintenance dose independently (in cases where the drug is prescribed subcutaneously or intramuscularly).

Chronic hepatitis B: Altevir ® is administered subcutaneously or intramuscularly at a dose of 5-10 million IU 3 times a week for 16-24 weeks. Treatment is stopped after 3-4 months of use in the absence of positive dynamics (according to a study of hepatitis B virus DNA).

Chronic hepatitis C: Altevir ® is administered subcutaneously or intramuscularly at a dose of 3 million IU 3 times a week for 24-48 weeks. In patients with a relapsing course of the disease and patients who have not previously received treatment with interferon alfa-2b, the effectiveness of treatment increases with combination therapy with ribavirin. The duration of combination therapy is at least 24 weeks. Therapy with Altevir should be carried out for 48 weeks in patients with chronic hepatitis C and the 1st genotype of the virus with a high viral load, in whom hepatitis C virus RNA is not detected in the blood serum by the end of the first 24 weeks of treatment.

Laryngeal papillomatosis: Altevir ® is administered subcutaneously at a dose of 3 million IU/m 2 3 times a week. Treatment begins after surgical (or laser) removal of the tumor tissue. The dose is selected taking into account the tolerability of the drug. Achieving a positive response may require treatment for 6 months.

Hairy cell leukemia: The recommended dose of Altevir for subcutaneous administration to patients after splenectomy or without it is 2 million IU/m 2 3 times a week. In most cases, normalization of one or more hematological parameters occurs after 1-2 months of treatment; it is possible to increase the treatment period to 6 months. This dosage regimen should be followed continuously unless rapid progression of the disease or symptoms of severe intolerance to the drug occur.

Chronic myeloid leukemia: The recommended dose of Altevir as monotherapy is 4-5 million IU/m2 per day subcutaneously every day. To maintain the number of leukocytes, a dose of 0.5-10 million IU/m2 may be required. If treatment allows you to control the number of leukocytes, then to maintain hematological remission the drug should be used at the maximum tolerated dose (4-10 million IU/m2 daily). The drug should be discontinued after 8-12 weeks if therapy does not lead to partial hematological remission or a clinically significant decrease in the number of leukocytes.

Non-Hodgkin's lymphoma: Altevir ® is used as adjuvant therapy in combination with standard chemotherapy regimens. The drug is administered subcutaneously at a dose of 5 million IU/m 2 3 times a week for 2-3 months. The dose must be adjusted depending on the tolerability of the drug.

Melanoma: Altevir ® is used as adjuvant therapy when there is a high risk of relapse in adults after tumor removal. Altevir ® is administered intravenously at a dose of 15 million IU/m 2 5 times a week for 4 weeks, then subcutaneously at a dose of 10 million IU/m 2 3 times a week for 48 weeks. The dose must be adjusted depending on the tolerability of the drug.

Multiple myeloma: Altevir ® is prescribed during the period of achieving stable remission at a dose of 3 million IU/m 2 3 times a week subcutaneously.

Kaposi's sarcoma due to AIDS: the optimal dose has not been established. The drug can be used in doses of 10-12 million IU/m2/day subcutaneously or intramuscularly. If the disease stabilizes or responds to treatment, therapy is continued until tumor regression occurs or drug discontinuation is required.

Kidney cancer: The optimal dose and regimen have not been established. It is recommended to use the drug subcutaneously in doses of 3 to 10 million IU/m 2 3 times a week.

Preparation of solution for intravenous administration

Draw up the volume of Altevir solution required to prepare the required dose, add it to 100 ml of sterile 0.9% sodium chloride solution and administer it over 20 minutes.

Side effect

General reactions: very often - fever, weakness (they are dose-dependent and reversible reactions, disappear within 72 hours after a break in treatment or its cessation), chills; less often - malaise.

From the side of the central nervous system: very often - headache; less often - asthenia, drowsiness, dizziness, irritability, insomnia, depression, suicidal thoughts and attempts; rarely - nervousness, anxiety.

From the musculoskeletal system: very often - myalgia; less often - arthralgia.

From the digestive system: very often - loss of appetite, nausea; less often - vomiting, diarrhea, dry mouth, change in taste; rarely - abdominal pain, dyspepsia; a reversible increase in liver enzyme activity is possible.

From the cardiovascular system: often - decreased blood pressure; rarely - tachycardia.

Dermatological reactions: less often - alopecia, increased sweating; rarely - skin rash, itching.

From the hematopoietic system: possible reversible leukopenia, granulocytopenia, decreased hemoglobin levels, thrombocytopenia.

Others: rarely - weight loss, autoimmune thyroiditis.

Contraindications to the use of the drug

- history of severe cardiovascular disease (uncontrolled chronic heart failure, recent myocardial infarction, severe heart rhythm disturbances);

- severe renal and/or liver failure (including those caused by the presence of metastases);

- epilepsy, as well as severe dysfunction of the central nervous system, especially expressed by depression, suicidal thoughts and attempts (including a history);

- chronic hepatitis with decompensated liver cirrhosis and in patients receiving or recently receiving treatment with immunosuppressants (with the exception of completed short-term treatment with corticosteroids);

— autoimmune hepatitis or other autoimmune disease;

- treatment with immunosuppressants after transplantation;

- a disease of the thyroid gland that cannot be controlled by generally accepted therapeutic methods;

— decompensated lung diseases (including COPD);

— decompensated diabetes mellitus;

- hypercoagulation (including thrombophlebitis, pulmonary embolism);

- severe myelodepression;

- pregnancy;

- lactation period (breastfeeding);

- hypersensitivity to the components of the drug.

Use of the drug during pregnancy and lactation

The drug is contraindicated during pregnancy and lactation (breastfeeding).

Use for liver dysfunction

Use for renal impairment

The drug is contraindicated in severe renal and/or liver failure (including those caused by the presence of metastases).

special instructions

Before treatment with Altevir for chronic viral hepatitis B and C, it is recommended to perform a liver biopsy to assess the degree of liver damage (signs of active inflammatory process and/or fibrosis). The effectiveness of treatment of chronic hepatitis C increases with combination therapy with Altevir and ribavirin. The use of Altevir is not effective in the development of decompensated liver cirrhosis or hepatic coma.

If side effects occur during treatment with Altevir, the dose of the drug should be reduced by 50% or the drug should be temporarily discontinued until they disappear. If side effects persist or recur after dose reduction, or disease progression is observed, treatment with Altevir should be discontinued.

If the platelet level decreases below 50x10 9 /l or the granulocyte level below 0.75x10 9 /l, it is recommended to reduce the Altevir dose by 2 times with blood test monitoring after 1 week. If these changes persist, the drug should be discontinued.

If the platelet level decreases below 25x10 9 /l or the granulocyte level below 0.5 x10 9 /l, it is recommended to discontinue the drug Altevir ® with blood test monitoring after 1 week.

In patients receiving interferon alpha-2b preparations, antibodies that neutralize its antiviral activity can be detected in the blood serum. In almost all cases, antibody titers are low, their appearance does not lead to a decrease in the effectiveness of treatment or the occurrence of other autoimmune disorders.

Overdose

Data on overdose of the drug Altevir ® are not provided.

Drug interactions

Drug interactions between Altevir and other drugs have not been fully studied. Altevir should be used with caution simultaneously with hypnotics and sedatives, narcotic analgesics and drugs that potentially have a myelosuppressive effect.

When Altevir and theophylline are prescribed simultaneously, the concentration of the latter in the blood serum should be monitored and, if necessary, its dosage regimen should be changed.

When Altevir is used in combination with chemotherapeutic drugs (cytarabine, cyclophosphamide, doxorubicin, teniposide), the risk of developing toxic effects increases.

Conditions for dispensing from pharmacies

The drug is available with a prescription.

Storage conditions and periods

The drug should be stored out of the reach of children, in accordance with SP 3.3.2-1248-03 at a temperature of 2° to 8°C; do not freeze. Shelf life - 18 months.

Transport at temperatures from 2° to 8°C; do not freeze.

• Clinical pharmacology

  Pharmacological action - antiviral, antitumor and immunomodulatory.

  It is a highly purified recombinant protein with a molecular weight of 19,300 daltons. Obtained from an E. coli clone by hybridizing a bacterial plasmid with the human leukocyte gene encoding the synthesis of interferon. Unlike interferon, alpha-2a has arginine at position 23. It has an antiviral effect, which is due to interaction with specific membrane receptors and the induction of RNA and ultimately protein synthesis. The latter, in turn, prevent the normal reproduction of the virus or its release. It has immunomodulatory activity, which is associated with the activation of phagocytosis, stimulation of the formation of antibodies and lymphokines. Has an antiproliferative effect on tumor cells.

  • Pharmacokinetics

    With intramuscular administration, 70% enters the systemic circulation. Biotransformed mainly in the kidneys and to a small extent in the liver. Interferon alfa-2b is excreted from the body by the kidneys.

• Indications for use
  • Chronic hepatitis B.
  • Chronic hepatitis C.
  • Mycosis fungoides.
  • Primary T-cell lymphosarcoma.
  • Hairy cell leukemia.
  • Multiple myeloma (generalized forms).
  • Chronic myeloid leukemia.
  • Malignant melanoma.
  • Bladder cancer (superficial).
  • Basal cell carcinoma.
  • Pointed condylomatosis.
  • Kaposi's sarcoma (including with AIDS).
  • Non-Hodgkin's lymphoma (as part of combination therapy).

• Directions for use and doses

  Individual, depending on the indications and treatment regimen.

  • For hairy cell leukemia

    Adults are administered intramuscularly or subcutaneously at 2 million IU/m2 3 times a week.

  • For Kaposi's sarcoma

    30 million IU/m 2 3 times a week.

• Contraindications
  • Severe cardiovascular diseases.
  • Severe liver and/or kidney dysfunction.
  • Epilepsy and/or serious functional disorders of the central nervous system.
  • Chronic hepatitis with the threat of developing liver cirrhosis.
  • Liver diseases in the decompensation phase.
  • Chronic hepatitis during or after previous therapy with immunosuppressants (with the exception of the condition after discontinuation of short-term therapy with corticosteroids).
  • Autoimmune hepatitis.
  • History of autoimmune diseases.
  • Transplant recipients are immunosuppressed.
  • Pre-existing thyroid diseases.
  • Hypersensitivity to interferon alpha-2b.

• Use during pregnancy and lactation

  Use during pregnancy is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus. Women of childbearing potential should use reliable methods of contraception while using interferon alfa-2b.

  If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.

• Interaction

  Interferons can enhance the neurotoxic, myelotoxic or cardiotoxic effects of drugs prescribed previously or simultaneously with them.

• Special conditions

  Should not be used in patients with a history of mental disorders. Use with caution in patients with a history of lung diseases (including chronic obstructive pulmonary disease), diabetes mellitus with a tendency to ketoacidosis, increased blood clotting (including a history of thrombophlebitis and pulmonary embolism), states of severe myelodepression.

  Before starting and systematically during the treatment period, liver function, peripheral blood patterns, biochemical blood parameters, and creatinine should be monitored. During the treatment period, adequate hydration of the body should be carried out. In patients with chronic hepatitis C, thyroid-stimulating hormone levels should be monitored during treatment.

  In chronic hepatitis B, accompanied by a decrease in the synthetic function of the liver (which manifests itself in a decrease in albumin levels or an increase in prothrombin time), the expected benefits and possible risks of therapy should be assessed. Use for concomitant psoriasis is justified in cases where the expected benefit of therapy outweighs the potential risk. If there is concomitant diabetes mellitus or arterial hypertension, an examination of the fundus of the eye is necessary before and during treatment. If there is a history of chronic heart failure, myocardial infarction and/or previous or existing arrhythmias, treatment with interferon alfa-2b should be carried out under the strict supervision of a physician.

  • Impact on the ability to drive vehicles and operate machinery

    Effect on the ability to drive vehicles and operate machinery. At the beginning of therapy, you should refrain from potentially dangerous activities that require increased attention and rapid psychomotor reactions, until the effect of interferon alfa-2b stabilizes.

  Interferon alpha-2b in the form of powder for injection and solution for injection is included in the List of Vital and Essential Drugs.

2018-02-02T17:43:00+03:00

Proven effectiveness of interferon alpha 2b

The world first learned about interferon, a natural protein in the human body, in 1957, when scientists Alik Isaacs and Jean Lindenmann discovered the phenomenon of interference, a complex mechanism of biological processes thanks to which the body is able to fight various diseases. But in the last century they probably did not suspect that this protein would become the main component of many medications.

Interferons are proteins that are produced by body cells when viruses invade them. Thanks to them, genes responsible for the synthesis of protective intracellular molecules are activated, which provide an antiviral effect by suppressing the synthesis of viral proteins and preventing its reproduction. In other words, these proteins (they are also called cytokines) in our body act as powerful defenders who guard our health and keep a strict vigil so that, if necessary, we can immediately repel the attack of viruses and defeat the disease.

To protect the body infected with viruses, interferon is produced by almost all cells of our body. In addition, its formation can be stimulated not only by viruses, but also by bacterial toxins, so this protein is also effective against some bacterial infections. Thus, we can conclude that this cytokine is a very important component of the human immune system. Without it, humanity would have been defeated long ago by numerous viruses and bacteria.

Types of interferons

Interferons are divided into three types: alpha, beta and gamma, which are produced by different cells.

• Interferon alpha activates the so-called natural killer cells - leukocytes, which destroy viruses, bacteria and other “enemy” agents.
• Interferon beta is produced in fibroblasts, epithelial cells and macrophages, which absorb infectious agents.
• Interferon gamma is produced by T-lymphocytes, its main function, like other types, is the regulation of immunity.

How has the effectiveness of interferon been proven for ARVI?

As is known, in their activities, when prescribing therapy, doctors rely on their experience and an already established system of knowledge. But medicine is developing rapidly: every year new effective treatment methods are developed around the world and new drugs are patented. Therefore, there was a need to systematize the latest achievements and discoveries in medicine, which resulted in clinical recommendations and treatment standards. These documented algorithms, based on proven clinical experience, describe the necessary instructions for diagnosis, treatment, rehabilitation, disease prevention and help the doctor make decisions on the choice of treatment tactics in a given situation.

For example, on the issues of providing medical care to children on the problem of acute respiratory viral infections and influenza, the development group consists of approximately 40 people and includes leading Russian specialists in the field of infectious diseases from different institutions and various departments. It is logical that experts pay special attention to medications that are able to cope with diseases as quickly as possible and at the same time have a minimum of side effects. Now we are talking about drugs containing interferon, which help fight ARVI in adults and children.

As mentioned above, their ability to fight viruses was discovered during the study of interference by scientists Isaacs and Lindenmann. They described interferon as “a protein, much smaller than immunoglobulins, that is produced by the body's cells after infection with live or inactivated viruses; capable of inhibiting the growth of a variety of viruses in doses that are non-toxic to cells.” Today it is known that these proteins can be produced by almost all cells of the body in response to the introduction of foreign information, regardless of its etiology (viruses, fungi, bacteria, intracellular pathogens, oncogenes). And their main biological effect lies in the processes of recognition and removal of this foreign information. In other words, these protective molecules “know how” to gently and accurately destroy viruses that have occupied cells, without damaging the cells themselves. This has been confirmed by numerous scientific studies.

As for the methods of using drugs containing interferons, it is necessary to mention some nuances. One of the main problems of interferon therapy is to “deliver” the effective dose of the drug without causing negative consequences. In some cases, intramuscular or intravenous administration of drugs containing interferon leads to side effects such as fever, chills, headache and other undesirable effects. These symptoms are not critical for the body and soon disappear, but during the treatment process they cause discomfort.

The use of suppositories containing interferon alfa-2b has made it possible to minimize the side effects of interferon therapy or to do without them altogether. According to scientific research, rectal use of recombinant human interferon in the first days of acute respiratory viral infection reduces the duration of fever, fights the runny nose and allows you to quickly defeat the disease 2. Intranasal use of drugs (when the medicine is applied to the nasal mucosa) containing interferon alfa-2b complements the treatment and ensures the optimal effect of therapy. One of the drugs that is suitable for fighting influenza and other acute respiratory viral infections at any stage of the disease is VIFERON. It is available in the form of suppositories (candles), gel and ointment.

Brief instructions for use and tolerability of drugs containing interferon alfa-2b

Who can take VIFERON drugs:

• adults;
• children from the first days of life;
• pregnant women from the 4th week of gestation.

Recognition by the scientific community

Interferon alfa-2b (VIFERON) is included in three federal standards of medical care as a recommended drug for the treatment of influenza and ARVI, as well as in three Federal Protocols for the treatment of these diseases. 1 If we take into account not only influenza and ARVI, but also other diseases, then the number of standards and recommendations regarding this drug is even greater - interferon (VIFERON) is included in 30 federal standards for the provision of medical care to adults and children, approved by the Ministry of Health of the Russian Federation, as well as in 21 Protocol (Clinical guidelines) for the provision of medical care to adults, including pregnant women, and children.

The principle of action of the drug

Human recombinant interferon alpha-2b, which is part of the drug VIFERON, has antiviral, immunomodulatory properties and suppresses the replication of RNA and DNA viruses. Antiviral therapy against influenza can be started at any phase of the disease. This will help improve the condition and prevent the development of complications 2. The drug VIFERON includes generally recognized highly active antioxidants: in suppositories these are vitamins E and C, in ointments - vitamin E, in gel - vitamin E, citric and benzoic acids. Against the background of such antioxidant support, an increase in the antiviral activity of interferons is noted.

Drug test results

VIFERON has undergone a full cycle of clinical trials for a wide range of different diseases in leading clinics in Russia. The result of the studies was evidence of the therapeutic and prophylactic effectiveness of the drug VIFERON for various infectious and inflammatory diseases in adults and children, including newborns, and pregnant women. It has been scientifically proven that the complex composition and release form provides the drug VIFERON with unique pharmacokinetic characteristics, with prolongation of the action of interferon in the absence of side effects inherent in parenteral preparations of recombinant interferons 3.

For what diseases are interferon-based drugs used?alpha-2 b

The drug VIFERON in the form of suppositories, gel and ointment is used to treat the following diseases:

• ARVI, including influenza;
• herpes;
• papillomavirus infection;
• enterovirus infection;
• laryngotracheobronchitis;
• chronic hepatitis B, C, D, including those complicated by cirrhosis of the liver;
• bacterial vaginosis;
• candidiasis;
• mycoplasmosis;
• ureaplasmosis;
• gardnerellosis.

The use of the drug VIFERON as part of complex antiviral therapy makes it possible to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.

General doctor

1. http://www.rosminzdrav.ru, Order of the Ministry of Health of the Russian Federation, http://www.raspm.ru; http://www.niidi.ru; http://www.pediatr-russia.ru; http://www.nnoi.ru
2. Nesterova I.V. “Interferon drugs in clinical practice: when and how,” “Attending Physician,” September 2017.
3. “VIFERON is a complex antiviral and immunomodulatory drug for the treatment of infectious and inflammatory diseases in perinatology.” (Guide for doctors), Moscow, 2014.

Sources used: http://www.lsgeotar.ru